Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cultured ascites tumor cells and their lipid-depleted variants, which contained 35-40% less membrane phospholipid and cholesterol, were used for fusion experiments with unilamellar lipid vesicles which were between 300 and 600 nm in diameter. Vesicle-cell interaction was followed by tracer studies using vesicles double-labeled in the lipid moiety, by vesicle-encapsulated [3H] dextran, and by measurements of energy transfer between N-(10-[1-pyrene]decanoyl)sphingomyelin-labeled vesicles and alpha-parinaric acid-labeled cells in the presence of poly(ethylene glycol) (PEG) as fusogen. The reaction rates measured with the radiolabeled vesicles were found to follow patterns similar to those obtained with the resonance energy transfer assay. This latter method revealed a vesicle-cell membrane fusion reaction, which was substantiated by radiolabeling the internal cellular compartment after treatment of the cells with [3H]dextran-encapsulated vesicles as shown by electron microscopic autoradiography on semi-thin sections. Endocytosis as a reaction mechanism can be excluded, since no energy transfer was observed at 25 degrees C in the absence of PEG. Investigations of vesicle bilayer order and fluidity on vesicle-cell interaction revealed optimal reactivity, with intermediate fluidity corresponding to cholesterol/phospholipid ratios between 0.7 and 1.0 and fluorescence depolarization (P) values of 0.18 and 0.21. Lipid depletion decreased the reaction velocity between cells and vesicles by about 20%, exhibiting V values of 33.2 mumol/min, as compared to the control of 41.4 mumol/min determined for 10(7) cells. The affinity constants for vesicle lipid were affected only slightly with Km values of 0.195 mM (0.210 mM). The activation energies for the reaction were calculated to give values of EA = 22.44 kJ/mol for the control and of EA = 20.4 kJ/mol for the modified cells. These data indicate that the decrease in membrane lipid content apparently has no major influence on the extent of the interaction.
 ...
PMID:Fusion of lipid vesicles with ascites tumor cells and their lipid-depleted variants. Studies with radioactive- and fluorescent-labeled vesicles. 246 Jan 41

The three pregnancy proteins, PP12, PP14, and PAPP-A, reviewed here are all produced by the endometrium under the influence of progesterone. Their production is low during the secretory phase and increases dramatically after decidualization and pregnancy. PP12 and PP14 are synthesized by the epithelial cells and PAPP-A is synthesized by the stromal cells. Reflecting perhaps the relative abundance of stromal cells, PAPP-A concentrations increase progressively to term, whereas the levels of PP12 and PP14 level off and even decline after the 20th week of gestation. These proteins are also found in nonpregnant subjects in extrauterine sites: follicles, follicular fluid, luteal cells, and fallopian tubes, and in males, in seminal vesicles and seminal fluid. PP12 has been found in several forms of cancer, although not with sufficient frequency to make it a useful tumor marker. The biologic function of these proteins is still subject to speculation, but they do reflect the biosynthetic capacity of decidualized endometrium, and especially PP14 may find clinical application in the management of infertility patients.
 ...
PMID:Three pregnancy proteins (PP12, PP14, and PAPP-A): their biological and clinical relevance. 246 25

The nutritional state of 99 patients with head and neck malignancies was assessed before, during and up to 18 weeks after radiotherapy (DXRT) using anthropometry, immunology and blood chemistry. 73 patients were fed orally during therapy, first with a normal diet and later, when the side effects of DXRT worsened, with a supplemental liquid formula diet. During the first two weeks 26 patients were treated with a PEG (percutaneous endoscopically controlled gastrostomy) and were fed mainly enterally with formula diets. The parameters of those patients fed orally during DXRT worsened rapidly and only recovered slowly and incompletely. On the contrary, in spite of their poor initial condition, the patients with PEG improved their state of nutrition, even during DXRT. Both the objective parameters of nutrition and the subjective condition of the patients were measured with the help of the "quality of life index". During DXRT the quality of life of both groups deteriorated equally. The objective parameters of nutrition showed that the patient's strength and the capacity for work remained constant. Unexpectedly, after DXRT only the orally fed patients were found to have an improved subjective condition, probably because the PEG patients were reminded of their disease by the tube, in spite of successful completion of tumor therapy. This undoubtedly impedes the return to normal family and working life. Early and consistent enteral diet with PEG helps to stabilize the state of nutrition of patients with head and neck cancer, and is recommended, especially for patients already suffering from malnutrition before starting an aggressive multimodal tumor therapy.
 ...
PMID:[Nutrition of ENT tumor patients treated with radiotherapy. Comparison of oral and enteral nutrition using percutaneous gastrostomy]. 250 81

We report a novel way of obtaining a monoclonal antibody to renal cell carcinoma (RCC). BALB/c mice were immunized with RCC cells (ACHN, ATCC CRL1611) and hyperimmunized spleen cells were fused with Sp/2 murine myeloma cell line by PEG 2000. Many hybridoma supernatants were screened by enzyme linked immunosorbent assay (ELISA). After the cloning by limiting dilution, we established a hybridoma reactive to RCCs and named it A25. It belonged to the IgG1 subclass of immunoglobulins. According to our results using ELISA, 4 of 5 RCC cell lines were reactive to A25, while the remaining 23 non RCC cell lines did not react. The supernatant from A25 was used as a primary antibody preparation for avidin-biotin complex immuno peroxidase staining of multiple cases of RCC, normal tissue, and other tumors. This antibody reacted with 3 of 3 grade 1 RCC, 10 of 11 grade 2 RCC and 0 of 3 grade 3 RCC. Proximal tubules of the kidney shared this antigen. However, cross reactivity of this antibody was observed to pyloric glands of the stomach and adenocarcinoma of the colon. The epitope of A25 seemed to originate from normal kidney tubules. Low grade tumors preserved this epitope well, but this character of the original tissue seemed to disappear as tumor grade increased.
 ...
PMID:[Production of monoclonal antibody to renal cell carcinoma]. 267 65

For the purpose of determining the significance of CGRP for endocrine tumors, we attempted to establish CGRP radioimmunoassay (RIA) system and to measure plasma CGRP levels in patients with endocrine tumor. One ml of plasma (EDTA-2K + aprotinin 500.KIE/ml) was applied to Sep-Pak C 18 column, and was eluted by 90% MeOH plus 0.1% TFA. The eluted samples were used for RIA. RIA was performed by two day-one day system (delayed assay). B/F separation was made by two Ab-PEG method. Cross-reactivity of antisera was 0.0025% and below 0.0001% against PTH and calcitonin in human, respectively. The standard curve of CGRP showed a dose response curve. Results of dilution and reproduction tests were excellent. Normal range of serum CGRP was 6.7 +/- 3.0 pg/ml (M +/- SD) and the cut-off level was determined to be 12.7 pg/ml. Plasma CGRP showed 128,323 and 2,010 pg/ml in three preoperative patients with medullary thyroid carcinoma, indicating extremely high levels. On the other hand, plasma CGRP levels increased in 2/7, 2/4, 2/5, and 0/3 in patients with parathyroid adenoma, benign insulinoma, carcinoid and pheochromocytoma, respectively. Correlation between CGRP level and calcitonin levels was significant (r = 0.789) in only 16 patients with medullary thyroid carcinoma. This study suggests that our CGRP RIA system was satisfactory for clinical use and measurement of CGRP may be potentially useful for clearing the pathophysiology of neuroendocrine tumors, although CGRP level was raised in patients with medullary thyroid carcinoma.
 ...
PMID:[Radioimmunoassay of plasma calcitonin gene-related peptide (CGRP) levels in patients with endocrine tumor]. 278 8

Modification of recombinant human interleukin 2 (rhIL-2) with monomethoxy polyethylene glycol has been shown to alter its pharmacokinetic properties. Therefore, we investigated the pharmacological parameters of schedule and dose in order to assess the impact on the in vivo antitumor activity of this modification. The antitumor efficacy, as well as the toxicity, of polyethylene glycol-interleukin 2 (PEG-IL-2) was compared to that of rhIL-2 in three transplantable syngeneic murine tumor models, Meth A fibrosarcoma, B16 melanoma, and Pan-02 pancreatic carcinoma. At equitoxic dose levels, the antitumor activity of PEG-IL-2 was far superior to that of rhIL-2 in all three tumor models. This efficacy of PEG-IL-2 was dose dependent and was greatest on a Q7D x 2 schedule in Meth A and B16. When the same total doses were further divided and delivered on any of several alternative schedules, either the efficacy was reduced or the toxicity of the treatments was increased. In Pan-02, a rhIL-2-resistant tumor, PEG-IL-2 treatment on either the Q7D x 2, Q4D x 3, or Q3D x 4 schedule resulted in approximately a 200% increase in lifespan; however, the toxicity of the treatment increased as the interval between doses was shortened. Simulations of the pharmacokinetic profiles of these various regimens suggested that the toxicity of PEG-IL-2 and rhIL-2 was related to the minimum plasma concentration that was obtained and the time interval between peak levels. The efficacy of the treatment was associated with the interleukin 2 plasma peak height, since a dose response was observed; however, peak plasma concentration did not appear to be the only parameter which determined efficacy. We hypothesize that this observed schedule dependence is also affected by the kinetics of the host's biological response to rhIL-2.
 ...
PMID:Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models. 281 8

The EBV-hybridoma system will be, at present, the best method for rescuing low-frequency tumor-reactive B-cell clones in cancer patients to produce human monoclonal antibodies reactive with tumor-related antigens. To improve this system, we established a nobel fusion partner, 3HL3-6J(C5), which produced hybridomas efficiently (greater than 2 x 10(-5)) after fusion with EBV-transformed B cell lines. TAPC-301 and C5TK1, anti-SRBC IgM and anti-HBs IgG producer, respectively, which provided by Prof. Y. Ono, were used as standard EBV-transformed B cell lines. Their hybridomas were good antibody producers (greater than 10 micrograms/10(6) cells/24 hrs) and their cloning was relatively easy. The fusion rate was improved further when electrofusion was carried out instead of the conventional PEG fusion. Using PBL from a hepatoma patient, human monoclonal autoantibodies reactive with some cytoskeleton structure were easily produced by means of this system.
 ...
PMID:[A strategy for the production of human monoclonal antibodies]. 285 41

The present study was undertaken to investigate how a somatostatin analog (201-995 Sandoz), which is now commonly used for treatment of patients with gut hormone-producing tumors, affects water and ion absorption and transit time in the normal jejunum. Six healthy volunteers were given somatostatin analog intravenously at a dose of 1 microgram/kg/hr. At the same time, jejunal water and ion movement and transit time were measured using the triple-lumen tube technique [perfusion of a plasma-like electrolyte solution with PEG as a nonabsorbable marker at a rate of 15 ml/min; dye dilution curves ([3H]mannitol, [14C]PEG, BSP) for determination of jejunal transit time]. During somatostatin analog administration, transit time through a 30-cm segment of perfused jejunum increased from 4.0 min to 17.0 min. While the somatostatin analog increased jejunal transit time, it had no effect on net water and electrolyte absorption under steady-state conditions. The effect of somatostatin analog on the proximal small bowel is similar to the action of an eight-times higher dose of intravenous native somatostatin previously studied. The effect of the analog on transit time suggests a potentially beneficial effect in patients with large-volume diarrhea in which no tumor or circulating secretagogue can be identified, such as in pseudopancreatic cholera syndrome.
 ...
PMID:Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. 288 8

The general principles of chemotherapy in oncology and the various types of antineoplastic drugs are discussed. Particular attention was paid to the results of chemotherapy in dogs and cats as reported in the literature. Chemotherapy is indicated in neoplastic disease characterised by early metastasis and/or local invasive growth. The results of chemotherapy in dogs and cats are so far moderate. Chemotherapy studies in the Netherlands are discussed: predictive in vitro, PEG-asparaginase studies in canine lymphosarcoma and regional perfusion in canine osteosarcoma.
 ...
PMID:[Chemotherapy of tumors in dogs]. 328 98

Between 1970 and 1985, 145 patients were treated for pituitary adenomas and 126 patients were available for analysis. Sixty patients were treated with surgery alone (Group I), 54 were treated with surgery and radiation therapy (Group II), and 12 received irradiation only without tissue diagnosis (Group III). Extent of tumor was evaluated by CT scan, PEG, and surgical reports. There were 22 microadenomas in Group I and only 1 microadenoma in Group II. The mean follow-up was 6.4 years, 85% (51/60) of patients in Group I, 93% of patients in Group II, and only 50% of those treated with irradiation alone achieved tumor control. With subsequent salvage treatment, overall tumor control in Group I was 97%. The mean time to recurrence was 3.7 years (Group I), 4.5 years (Group II), and 4 years (Group III). In summary, combined treatment is effective to decrease the chance of local recurrence of pituitary adenomas. Nevertheless, because of successful salvage treatment after surgical failure, overall outcome is similar. Without persistent symptom after surgery or large residual tumor in or near the critical structures, postoperative irradiation can be deferred until tumor regrowth.
 ...
PMID:Radiotherapy in the treatment of pituitary adenomas. 340 14


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>